An in-depth look to SYNMOSA BIOPHARMA CORP operating, investing, and financing activities

4114 free cash flow for Q3 24 is 192.07 M TWD. For 2023, 4114 free cash flow was 262.31 M TWD and operating cash flow was 469.36 M TWD.